Surging Postpartum Use of GLP-1 Weight Loss Drugs Revealed in New Study

The landscape of modern medicine has shifted dramatically over the past several years, driven largely by the extraordinary rise of GLP-1 receptor agonists. Drugs such as Ozempic, Wegovy, and Mounjaro have transitioned from niche treatments for type 2 diabetes into cultural and clinical powerhouses. This year, the number of American adults utilizing a GLP-1 medication for weight loss reached an astonishing 11%, meaning that more than one in ten adults are now taking one form or another of these injectable treatments.

This explosion in utilization has occurred over a remarkably brief span—roughly five years—despite the underlying drug class having been on the market for more than two decades. The primary driver of this widespread adoption is simple efficacy: the medications work. Clinical data indicates that patients lose, on average, 7% to 11% of their starting body weight. Beyond simple weight management, researchers have identified a growing array of unexpected systemic benefits associated with GLP-1 medications. Studies have linked them to a lowered risk of depression, potential preventative effects against dementia, and reduced risks of cancer, heart attacks, and even substance abuse disorders.

Still, the vast majority of patients initiate therapy primarily to shed excess pounds. This trend is reflected across various demographics, but it is accelerating with unprecedented velocity in one specific group: new mothers. Recent research shows that the use of GLP-1 medications among women within six months of giving birth has skyrocketed, moving from a mere 0.8% in 2018 to 1.9% by 2025, representing a staggering 24-fold increase.

This new data sheds valuable light on broader demographic trends surrounding GLP-1 prescriptions. Overall, women utilize these medications at significantly higher rates than men, comprising as much as 70% of the total patient population taking the drugs.

New Moms on the Jab

To better understand these patterns, researchers conducted a comprehensive study examining one million births, closely tracking which mothers initiated GLP-1 therapy within the first six months postpartum. The findings revealed distinct behavioral trends across different medical categories within this cohort.

Among new mothers with pre-existing type 2 diabetes, prescription rates saw a dramatic climb, moving from 2.3% to 16.9%—equivalent to roughly one in six patients—between 2018 and 2025. Concurrently, women who experienced gestational diabetes, a temporary form of diabetes that develops during pregnancy, also dramatically increased their uptake of GLP-1 prescriptions, rising from 0.4% in 2021 to 2.7% in 2025.

Gestational diabetes is diagnosed in roughly 5% to 9% of all pregnancies in the United States and serves as a strong clinical indicator that a mother is at elevated risk for developing chronic metabolic disease later in life. Data shows that as many as 50% to 70% of women who experience gestational diabetes go on to develop type 2 diabetes years down the line.

However, the most rapid acceleration occurred among women who were clinically diagnosed as obese or overweight prior to their pregnancies. For this group, GLP-1 prescriptions surged from 0.4% in 2021 to 3.9% in 2025, marking nearly a tenfold increase in just four years.

This shift mirrors the broader history of the drug class itself. GLP-1 medications were not always approved or widely prescribed for primary weight management; they were initially developed to assist diabetic patients in regulating blood sugar levels. However, a major regulatory shift in 2021 altered that landscape, opening the door for individuals struggling with chronic weight management and obesity to access the treatments, thereby igniting the massive commercial and clinical frenzy observed today.

Losing Pregnancy Weight

The surge in postpartum prescriptions highlights a persistent clinical challenge: weight gained during pregnancy can be exceptionally difficult to lose long after childbirth. Authors of the research note that up to 75% of women weigh more twelve months after giving birth than they did prior to becoming pregnant. This retained postpartum weight frequently contributes to compounding health risks, including elevated blood pressure, adverse cholesterol levels, and increased insulin resistance.

Long-term epidemiological studies suggest that failing to return to pre-pregnancy weight by one year postpartum is a reliable indicator of sustained higher weight fifteen years into the future. Because GLP-1 medications are generally contraindicated and carefully avoided during pregnancy itself, the immediate postpartum period—specifically the first six months after birth—has emerged as a critical window for intervention. Researchers emphasize that these therapies can serve as vital clinical tools to manage the long-term metabolic risks associated with postpartum weight retention and diabetes development.

At the same time, the timing of these prescriptions has raised important clinical questions. Because mothers are initiating therapy so soon after delivery, study authors are calling for more extensive research into how GLP-1 medications might interact with breastfeeding. While preliminary data from at least one study indicated that GLP-1 components were undetectable in breast milk, medical experts continue to advise a high degree of caution, and many healthcare providers currently recommend against using the drugs while actively breastfeeding.